ArticleClinical cancer research : an official journal of the American Association for Cancer Research2008
Ascites specific inhibition of CD1d-mediated activation of natural killer T cells.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Review
- VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional.Cytokine · 2015Article
- Natural killer T (NKT) cells accelerate Shiga toxin type 2 (Stx2) pathology in mice.Frontiers in microbiology · 2015Article
- CD1d levels in peripheral blood of patients with acute myeloid leukemia and acute lymphoblastic leukemia.Oncology letters · 2014Article
- Natural killer T cell based Immunotherapy.Journal of vaccines & vaccination · 2012Article
- Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer.Cancer research · 2012Article
- Oxidative dna damage of lymphocytes in peripheral blood and ascites in cancer patients.Current oncology (Toronto, Ont.) · 2012Article
- Invariant NKT cells as novel targets for immunotherapy in solid tumors.Clinical & developmental immunology · 2012Review
- CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.Cancer research · 2011Article
- Dietary fatty acids modulate antigen presentation to hepatic NKT cells in nonalcoholic fatty liver disease.Journal of lipid research · 2010Article
- The detection, treatment, and biology of epithelial ovarian cancer.Journal of ovarian research · 2010Article
- Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.Clinical & developmental immunology · 2010Review
- Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells.Journal of immunological methods · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
purposeNatural killer T (NKT) cells recognize lipid antigen presented by CD1 molecules. NKT cells can both directly, through cytotoxicity, and indirectly, through activation of other effector cells, mediate antitumor immunity. It has been shown, however, that tumor-associated lipids are frequently shed into the tumor microenvironment, which can mediate immunosuppressive activity. Given that ovarian cancer-associated ascites has been reported to have increased levels of gangliosides, we examined the effect of tumor-associated and other ascites on CD1d-mediated antigen presentation to NKT cells. EXPERIMENTAL
designTo investigate the effects of ascites on NKT cell activation, we pretreated CD1d-expressing cells with the ascites and measured their ability to stimulate cytokine production in NKT cells. To determine whether antigen processing or editing was necessary, CD1d-immunoglobulin-based artificial antigen presenting cells (aAPC) were also incubated with ascites. In addition, to examine specificity, we analyzed whether ascites fluid could influence the activation of classic CD8+ T cells.
resultsPretreatment of CD1d-expressing cells with ascites from the majority of patients inhibited the ability of the cells to stimulate/activate NKT cells in a dose-dependent manner. Ascites treatment also partially blocked the ability of alpha-galactosylceramide-loaded CD1d-immunoglobulin-based aAPC to activate NKT cells. In addition, our data show that treatment with ascites does not inhibit HLA-A2-mediated activation of classic CD8+ T cells.
conclusionsTogether, these data suggest that ovarian and other cancers may have developed immune evasion mechanisms specifically targeting the CD1/NKT cell system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.